The FDA rejected Eli Lilly's studies comparing small-scale batches of Byetta LAR made by partner Alkermes to large-scale batches made at an Amylin Pharmaceuticals manufacturing plant, Amylin said. Conducting a new study could delay the company's plans to seek approval next year, the Indianapolis Star reported.
The version of Byetta currently on the market is a twice-a-day injectable drug to help diabetics control their blood sugar, the newspaper said.
Teacher apologizes for showing sexual image of herself in class
Dennis Rodman pledges to end trips to North Korea